| Primary information |
|---|
| SALID | SAL_16116 |
| Biomarker name | L-phenylalanine |
| Biomarker Type | Diagnostic |
| Sampling Method | Saliva samples were collected from a group of 30 OSCC patients (25 men and 5 women, 7 of stage I, 6 of stage II, 2 of stage III and 15 of stage IV), whose mean age was 62 years and control samples from a group of 60 healthy individuals, cancer-free individuals with 35 males and 25 females. |
| Collection Method | Roughly 3 mL of clear unstimulated whole saliva was obtained. The samples, once collected, were centrifuged at 2500 rpm for 15 min at 4 degree C. |
| Analysis Method | UPLC-ESI-MS |
| Collection Site | Whole Saliva |
| Disease Category | Cancer |
| Disease/Condition | Oral Cancer |
| Disease Subtype | Oral squamous cell carcinoma (OSCC) |
| Fold Change/ Concentration | NA |
| Up/Downregulated | Decrease |
| Exosomal | NA |
| Organism | Homo sapiens |
| PMID | 24401418 |
| Year of Publication | 2014 |
| Biomarker ID | 6140 |
| Biomarker Category | Metabolite |
| Sequence | C1=CC=C(C=C1)C[C@@H](C(=O)O)N |
| Title of study | Measurement of salivary metabolite biomarkers for early monitoring of oral cancer with ultra performance liquid chromatography-mass spectrometry |
| Abstract of study | This study aimed to set-up an ultra performance liquid chromatography-electrospray ionization-mass spectrometry (UPLC-ESI-MS) method for the determination of salivary L-phenylalanine and L-leucine for early diagnosis of oral squamous cell carcinoma (OSCC). In addition, the diagnostic accuracy for both biomarkers was established by using receiver operating characteristic (ROC) analysis. Mean recoveries of l-phenylalanine and L-leucine ranged from 88.9 to 108.6% were obtained. Intra- and inter-day precision for both amino acids was less than 7%, with acceptable accuracy. Linear regression coefficients of both biomarkers were greater than 0.99. The diagnostic accuracy for both biomarkers was established by analyzing 60 samples from apparently healthy individuals and 30 samples from OSCC patients. Both potential biomarkers demonstrated significant differences in concentrations in distinguishing OSCC from control (P<0.05). As a single biomarker, L-leucine might have better predictive power in OSCC with T1-2 (early stage of OSCC including stage I and II), and L-phenylalanine might be used for screening and diagnosis of OSCC with T3-4 (advanced stage of OSCC including stage III and IV). The combination of L-phenylalanine and L-leucine will improve the sensitivity (92.3%) and specificity (91.7%) for early diagnosis of OSCC. The possibility of salivary metabolite biomarkers for OSCC diagnosis is successfully demonstrated in this study. This developed method shows advantages with non-invasive, simple, reliable, and also provides lower detection limits and excellent precision and accuracy. These non-invasive salivary biomarkers may lead to a simple clinical tool for the early diagnosis of OSCC. |